



CURRICULUM VITAE (CVA)

Part A. PERSONAL INFORMATION

CV date	12/2021
----------------	---------

First name	Fernando		
Family name	Calvo	Age	43
Gender (*)	Male	Birth date	14/09/1978
ID number	72037483-B	e-mail	calvof@unican.es
URL Web	https://web.unican.es/ibbttec/r/FernandoCalvoLab		
Open Researcher and Contributor ID (ORCID) (*)	0000-0001-8858-1185		

A.1. Current position

Position	Científico Titular CSIC		
Initial date	01/12/2021		
Institution	Centro Superior de Investigaciones Científicas (CSIC)		
Department/Center	Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC)		
Country	Spain	Phone number	(+34) 942-206825
Key words	cancer, tumour microenvironment, cancer-associated fibroblasts, signalling, transcription		

A.2. Previous positions (research activity interruptions, art. 14.2.b)

Period	Position/Institution/Country/Interruption cause
03/2018 – 11/2021	Ramón y Cajal Researcher / IBBTEC-CSIC/ Spain
10/2013 – 02/2018	Team Leader / Institute of Cancer Research / UK
01/2010 – 09/2013	Postdoctoral Researcher Sahai Lab / London Research Institute / UK
10/2008 – 12/2009	Postdoctoral Researcher Crespo Lab / IBBTEC-CSIC / Spain
10/2002 – 09/2008	FPU PhD Student Crespo Lab / IBBTEC-Universidad de Cantabria / Spain
09/2001 – 08/2002	Industrial Placement Intern / AstraZeneca Pharmaceuticals / UK

A.3. Education

Degree	University/Country	Year
PhD	Universidad de Cantabria / Spain	2008 (October)
BSc Biochemistry	Universidad del País Vasco / Spain	2001

Part B. CV SUMMARY

Fernando obtained his PhD with Piero Crespo in Santander (Spain) studying Ras GTPases. He then carried out post-doctoral work in London (Erik Sahai) where he studied cancer metastasis and the tumour microenvironment. In 2013, he set up his own independent group at the ICR (London, UK). In 2018, Fernando returned to Santander where he leads the Tumour Microenvironment Team at the IBBTEC. His group uses a wide range of techniques from conventional cell and molecular biology, through *in vivo* models and analysis of clinical material, to study the role of the tumour microenvironment in cancer progression. Fernando's work has led to 35 publications (h-index:19; Q1: 20; D1: 10; total citations: 1,670; total IF: 226), including 16 as first/corresponding author and articles in prestigious journals such as *Cancer Cell*, *Nat Cell Biol*, and *Nat Commun*. In addition, Fernando has obtained competitive funding at all stages of his career including the prestigious FPU Studentship (2003), CRUK Postdoctoral Fellowship (2010), Worldwide Cancer Research Grant, CRUK Collaborative Award, Ramón y Cajal Fellowship, Lab-AECC, Proyectos Coordinados AECC, and *Plan Nacional* Projects (8 major grants as PI in UK and Spain). Additional indicators of esteem include 49 seminars at Universities and Conferences and peer-reviewing at top journals and funding agencies. He has directed one completed PhD Thesis (plus 5 ongoing) as well as numerous MSc and BSc students.

Part C. RELEVANT MERITS

C.1. Publications

· Ten most relevant publications | Full list (35): <https://orcid.org/0000-0001-8858-1185>

‡, F Calvo, Corresponding Author | #, F Calvo, First Author | (x/n) Position | (AC) Corresponding Author.



1. † (6/6) Farrugia AJ, Rodríguez J, Orgaz JL, Lucas MJ, Sanz-Moreno and **Calvo F (AC)** (2020). “CDC42EP5/BORG3 modulates SEPT9 to promote actomyosin function, migration and invasion”. **Journal of Cell Biology** 219(9):e201912159 | *IF:10.539, Rank 28/195, Q1, Percentile:85.90*.
2. (26/35) Woolston A, Khan K, Spain G, ..., Gerlinger M (AC) (2019). “Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer”. **Cancer Cell** 36(1):35-50 | *Editorial in Cancer Cell 36(1):1-3 and Nat Rev Clin Oncol 16(9):527 | IF:26.602, Rank 4/195, D1, Percentile:98.205, Citations Scopus:75*.
3. † (18/19) Perone Y, Farrugia AJ, Rodríguez-Meira A, ..., **Calvo F (AC)**, Magnani L (AC) (2019). “SREBP1 drives Keratin 80-dependent cytoskeletal changes and invasive behavior in endocrine resistant ER α breast cancer”. **Nature Communications** 10(1):2115 | *IF:12.121, Rank 6/71, D1, Percentile:92.254*.
4. † (12/12) Ferrari N, Ranftl R, Chicherova I, ..., **Calvo F (AC)** (2019). “Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts”. **Nature Communications** 10(1):130 | *IF:12.121, Rank 6/71, D1, Percentile:92.254*.
5. (10/11) Avgustinova A, Irvani M, Robertson D, ..., **Calvo F**, and Isacke CM (AC) (2016). “Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness”. **Nature Communications** 7:10305 | *IF:12.124, Rank 3/64, D1, Percentile:96.094*.
6. # † (1/9) **Calvo F (AC)**, Ranftl R, Hooper S, ..., Sahai E (AC) (2015). “Cdc42EP3/BORG2 and septin network enables mechano-transduction and the emergence of cancer-associated fibroblasts”. **Cell Reports** 13(12):2699-714 | *IF:7.870, Rank 27/184, Q1, Percentile:85.598*.
7. (2/10) Herraiz C, **Calvo F**, Pandya P, ..., Sanz-Moreno V (AC) (2015). “Reactivation of p53 by a cytoskeletal sensor to control the balance between DNA damage and tumor dissemination”. **Journal of the National Cancer Institute** 108(1):djv289 | *IF:12.589, Rank 9/217, D1, Percentile:96.083*.
8. † (2/2) Ferrari N & **Calvo F (AC)** (2014). “Tumor Microenvironment: Unleashing metalloproteinases to induce a CAF phenotype”. **Current Biology** 24(20):R1009-11 | *IF:9.571, Rank 15/290, D1, Percentile:95.000*.
9. # (1/11) **Calvo F**, Ege N, Grande-Garcia A, ..., Sahai E (AC) (2013) “Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts”. **Nature Cell Biology** 15(6):637-46 | *Editorial in Nat Cell Biol 15: 570-573 (2013) | IF:20.058, Rank 7/185, D1, Percentile:96.486*.
10. # (1/7) **Calvo F**, Sanz-Moreno V, Agudo-Ibáñez L, Wallberg F, Sahai E, Marshall CJ and Crespo P. (2011). “RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation”. **Nature Cell Biology** 13(7):819-26 | *Faculty of 1000 score: 1 | IF:19.488, Rank 6/181, D1, Percentile:96.961*.

C.2. Congress

Organiser and Chair

- (2021) SEBBM Elevator Pitch dedicated to IBBTEC, Santander (co-organiser and chair)
- (2015-2018) Internal Seminars (weekly) and Scientific poster sessions (bi-monthly) for the Divisions of Cancer Biology, Structural Biology and Breast Cancer Research, ICR, UK.
- (2014) ICR Tumour Microenvironment Session, Institute of Cancer Research Faculty Retreat, UK | Light Microscopy Workshop, ICR, UK | Grand Talks. “Tumour Microenvironment: a driver of tumour progression and evolution”, ICR, UK.

Seminars at Conferences and Meetings (per year, last 5 years, from a total of 21)

- (2021) “SEBBM Elevator Pitch”, *invited talk*, Spain, Online | “3rd ASEICA Educational Symposium”, *invited talk*, Spain, Online.
- (2019) “SRUK Cancer Networking Series”, *invited talk*, Manchester, UK | “VI Workshop on Mechanisms of Cell Adhesion, Migration and Invasion”, *invited talk*, Badajoz, Spain | “Workshop YAP/TAZ and TEAD: At the Crossroads of Cancer”, *invited talk*, Telluride Science Research Center, USA | “EMBO Workshop: Mesenchymal cells in inflammation, immunity and cancer”, *selected talk*, Athens, Greece | “Meeting of the National Mechanobiology Network (MEC2BIO)”, *invited talk*, Zaragoza, Spain.
- (2018) “16th Spanish Association for Cancer Research ASEICA Conference”, *selected talk*, Valencia, Spain | “New technologies in cancer mechanobiology”, *invited talk*, The Royal Society - Kavli Centre, UK | “London Motility Club”, *invited talk*, Laboratory for Molecular & Cell Biology, University College London, UK.
- (2017) “Brighton and Sussex Cancer Research Network symposium”, *invited talk*, University of Sussex, UK | “EMBO Workshop: Molecular and cellular biology of septins”, *selected talk*, Berlin, Germany | “Budapest Cancer Think Tank”, *invited talk*, Budapest, Hungary.



- (2016) “3rd International Mouse Models of Skin Cancer Meeting”, *invited talk*, Nice, France | “Spanish Biochemical and Molecular Biology Society Conference – Emerging Talent Workshop”, *selected talk*, Salamanca, Spain | “UK Breast Cancer Research Symposium”, *invited talk*, London UK | “31st European Cytoskeletal Forum-Cell Adhesion & Migration”, *invited talk*, Cambridge, UK.

Invited Seminars at University and Research Institutes (per year, last 5 years, from a total of 29)

- (2021) Centro Nacional de Investigaciones Oncológicas – Madrid, Spain | Centro de Investigaciones Biológicas – Madrid, Spain | Institute for Research in Biomedicine – Barcelona, Spain.
- (2020) Max-Planck Institute of Biochemistry, Department of Molecular Medicine – Munich, Germany | Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain.
- (2019) Universidad de Barcelona – Facultad de Medicina, Spain | CIC BioGUNE, Derio, Spain | BioDonostia Health Institute, San Sebastian, Spain.
- (2017) Institute of Reproductive and Developmental Biology, Imperial College London, UK. | Institut Jacques Monod, Paris, France. | Barts Cancer Institute, Queen Mary University of London, UK. | Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- (2016) Division of Cancer Research, University of Dundee School of Medicine, Dundee, UK. | Institute of Biomedicine & Biotechnology of Cantabria, CSIC-Universidad de Cantabria, Santander, Spain. | Department of Medical Physics & Biomedical Engineering, University College London, UK. | Department of Biology, Freie Universität Berlin, Germany | Developmental Biology & Cancer Programme, UCL Institute of Child Health, UK.

C.3. Research projects

Grants as PI (Agency and year | Title | Reference | Dates | Amount | Participation)

- **ERC Consolidator Grant 2021** | “Harnessing Stromal Fibroblasts to Reduce Resistance and Improve Colon Cancer Therapeutics” | *Pending resolution expected Jun 2022* | €2,000,000 | IP.
- **Equipamiento Científico-Técnico – AEI 2021** | “Microscopy platform with super-resolution and high content analysis (HCA) capabilities” | EQC2021-007003-P | 2021-2022 | €498,500 | co-IP (IP: Ignacio Varela, IBBTEC, Spain).
- **AECC Proyectos Coordinados 2020** | “Multidisciplinary dissection of the chemotherapy resistance mechanisms in triple negative breast cancer: A step towards improved clinical care” | PRYCO211372RODR | Oct 2021-Sept 2026 | €1,200,000 (€200,000 to FC) | co-IP (IP: Angel Nebreda, IRB, Spain).
- **AECC – LAB AECC 2019** | “Targeting cancer-associated fibroblasts using HDAC inhibitors to improve therapies for breast, ovarian and colon cancers” | LABAE19044CALV | Dec 2019-May 2023 | €274,014 | IP.
- **BBVA Leonardo Awards 2019** | “Cortocircuitar el microambiente tumoral para entorpecer el desarrollo de cánceres agresivos” | IN[19]_BBM_BAS_0076 | Jan 2020-Mar 2021 | €40,000 | IP.
- **Proyectos de I+D+i RETOS INVESTIGACIÓN-MINECO 2018** | “Identification and characterization of strategies to modulate cancer-associated fibroblasts to deter tumour progression (STOPCAF)” | RTI2018-096778-A-I00 | Jan 2019-Dec 2021 | €169,400 | IP.
- **Ramón y Cajal Research Fellowship 2016** | RYC-2016-20352 | Mar 2018-Feb 2023 | €208,000 (including salary and research support) | IP.
- **Cancer Research UK Multidisciplinary Project Award 2016** | “Investigating the physical and biological determinants of cancer cell extravasation” | C57744/A2367 | Apr 2017-Mar 2021 | £500,000 | IP (with E. Moendarbary, UCL, UK).
- **Worldwide Cancer Research 2015** | “Investigating the role of stromal Dkk3 in breast cancer progression and metastasis” | 15-0273 | Jan 2015-Dec 2018 | £223,737 | IP.

Studentships/fellowships to my group as PI

- **Universidad de Cantabria – PhD Studentship** | Apr 2021-Mar 2025 | Beatriz Rodríguez
- **Proyectos de I+D+i RETOS - FPI Studentship** | Oct 2020-Sept 2024 | Maria Subijana
- **AECC – Cantabria – PhD Studentship** | Dec 2019-Dec 2023 | Silvia Domínguez
- **Institute of Cancer Research – PhD Studentship** | Apr 2017-Mar 2021 | Maria Semiannikova
- **Institute of Cancer Research – PhD Studentship** | Oct 2014-Sept 2018 | Aaron Farrugia

C.4. Contracts, technological or transfer merits

- **Institute of Cancer Research (UK) - CSIC Collaborative Agreement** | Oct 2018-Sept 2020 | £85,000 | IP.



- **Institute of Cancer Research (UK) - Start-up funding** | Oct 2013-Sept 2018 | Institutional start-up funding a multiphoton intravital microscope and consumables and salaries for a postdoctoral fellow (Aug 2015-Mar 2018) and a scientific officer (Mar 2014-Feb 2017).

C.5. Merits, Awards and Fellowships

· Most relevant awards and merits (last ten years).

Six-year Term Evaluations (*Sexenios de investigacion*): 3 (2003-2008; 2009-2014; 2015-2020).

(2021) Shortlisted for CRIS-Cancer Award and ERC CoG.

(2020) Public Job Offer – *Científico Titular* CSIC – Score 57/60 (Top 1% of 314 exams) | Shortlisted for CRIS-Cancer Award.

(2019) Eaton Foundation Fellow (Telluride Science Research Center, Colorado, USA).

(2018) Best Oral Communication, Aseica Conference

(2016) Ramón y Cajal Research Fellowship | Shortlisted for CRUK Career Establishment Award | Biochemical Society Conference Bursary.

(2015) Shortlisted for MRC Career Development Award.

(2014) Shortlisted for Sir Henry Dale Fellowship Award.

C.6. Teaching and supervising

PhD Students –

- IBBTEC: Five PhD Students (ongoing): Catalina Capó (expected 05/2024), Silvia Domínguez (02/2024), María Subijana (09/2024), Beatriz Rodríguez (03/2025) y Diane Coursier (12/2024).
- Aaron Farrugia (ICR) | 2014 – 2018 | Now at the Mechanobiology Institute (Singapore)
- Maria Semiannikova (ICR) | 2017- 2023.

Other Students –

- MSc: Ievgeniia Chicherova (ICR); 2017 (6 months); now PhD Student at CRC - Lyon, France | Carla Portulano (IBBTEC); 2022 (9 months).
- JAE-Intro: David García (IBBTEC); 2020 (7 months); now PhD Student at Instituto de Neurociencias de Alicante, Spain | Ignacio Marina (IBBTEC); ongoing.

Postdoc –

- Dr Javier Rodríguez (IBBTEC) | Feb 2019-present.
- Dr Maxine Lam (ICR) | Apr 2017-Dec 2019 | Now at Mechanobiology Institute, Singapore.
- Dr Nicola Ferrari (ICR) | Jan 2015 – Aug 2017 | Now at Astex Pharmaceuticals, UK.

Others -

Fractional Lecturer. MSc Molecular Biology and Biomedicine. University of Cantabria (2021-present) | Faculty at PhD Programme in Biomedicine, Universidad de Cantabria, Spain (2018-present) | Athena Swan Silver Steering Committee Member - Institute of Cancer Research (2015-2017). *On April 2016 the ICR obtained the Athena Swan Silver Award.* | Supervisor of Intravital Imaging and Multiphoton Microscopy Unit at the Institute of Cancer Research (2013-2018) | Fractional Lecturer. MSc Oncology - Institute of Cancer Research (2014-2018).

C.7. Peer Reviewing, Evaluation, Committees and Scientific Dissemination

- Participation in the writing of the CSIC White Book 2030 (Scientific Challenge 4A, Cancer): Strategic plan for Research at CSIC for next 10 years (2020)
- *Member of Evaluating Commission* Agencia Estatal de Investigación – National Research Program Board - Biomedicine – Cancer Subgroup (2020).
- *Expert reviewer* for funding agencies (public and private) in Spain (Agencia Estatal de Investigación), UK (MRC, CRUK, Wellcome, UKRI, WCR), Austria, Sweden, Poland, Argentina.
- *PhD Examiner*: Steven Reid (2016, Beatson Institute, UK), Misa Ogura (2016- Crick Institute, UK), Roberto Moreno Vicente (2018 – CNIC, Spain), Aida Mestre (2020- U. Pompeu Fabra, Spain).
- *Editorial Board* of Scientific Reports (2019-, edited 2 manuscripts) and Bio-protocol.org (2013-), edited 5 manuscripts); *Review Editor* Frontiers in Cell and Developmental Biology (2021-)
- *Ad hoc* reviewer for Nat Mat, Nat Commun, Elife, Oncogene, Clin Cancer Res, Curr Biol, Cell Rep, J Pathol, J Cell Biol, and many others.

C.8. Other Merits

Member of (in italics, discontinued membership): SEBBM Consul (2022-present) | Excellence Network URONCOMOL (2021-present) | Working group ASEICA-Joven/Young-Aseica (2019-present) | SEBBM-part of FEBS (2009-present) | ASEICA-part of EACR (2009-present) | *National Mechanobiology Network (2019-2021)* | *Royal Biochemical Society, UK (2016-2018)* | *American Association for Cancer Research (2014-2018)* | *British Association for Cancer Research (2013-2018)*.